Skip to main content
Top
Published in: Respiratory Research 1/2012

Open Access 01-12-2012 | Review

Statins as potential therapeutic drug for asthma?

Authors: Cheng Yuan, Lin Zhou, Jiyun Cheng, Jingying Zhang, Yue Teng, Mao Huang, Ian M Adcock, Peter J Barnes, Xin Yao

Published in: Respiratory Research | Issue 1/2012

Login to get access

Abstract

Background

Statins are lipid-lowering agents that also exhibit pleiotropic effects in decreasing oxidative stress and inflammation. There have been several published studies reporting the use of statins in the treatment of asthma patients, but their results are not consistent. The aim of this study is to determine whether statins are beneficial for asthma administration, and explore the potential covariables that may affect their clinical effectiveness.

Methods

A systematic literature search was performed in PubMed, Embase and Cochrane Center Register of Controlled Trials from inception to September 2012. Randomized controlled trials (RCT), retrospective studies and controlled clinical trials which reported the use of statins in the treatment of asthma patients were eligible. Quality evaluation was conducted for RCT using Jadad criteria.

Results

A total of 18 articles were included. In our study, we found no conclusive evidence to demonstrate that statins could enhance the lung function in asthmatics, although, they may reduce airway inflammation. Additionally, the results were not consistent across studies with respect to symptoms, quality of life, maintenance medication, asthma hospitalization/emergency department (ED) visits.

Conclusions

Statins may reduce airway inflammation in asthmatics, without having a significant effect on lung function. Further large sample and multicenter clinical trials are needed to confirm this and to see if there are more responsive phenotypes of asthma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Riccioni G: Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem. 2007, 14 (18): 1966-1977. 10.2174/092986707781368522.PubMedCrossRef Riccioni G: Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem. 2007, 14 (18): 1966-1977. 10.2174/092986707781368522.PubMedCrossRef
2.
3.
go back to reference Thomson NC, Chaudhuri R: Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med. 2009, 15 (1): 39-45. 10.1097/MCP.0b013e32831da894.PubMedCrossRef Thomson NC, Chaudhuri R: Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med. 2009, 15 (1): 39-45. 10.1097/MCP.0b013e32831da894.PubMedCrossRef
4.
go back to reference Peters-Golden M, Swern A, Bird SS, et al: Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006, 27: 495-503. 10.1183/09031936.06.00077205.PubMedCrossRef Peters-Golden M, Swern A, Bird SS, et al: Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006, 27: 495-503. 10.1183/09031936.06.00077205.PubMedCrossRef
5.
go back to reference Farah CS, Kermode JA, Downie SR, Brown NJ, Hardaker KM, Berend N, King GG, Salome CM: Obesity Is a Determinant of Asthma Control. 2011, Chest: Independent of Inflammation and Lung Mechanics Farah CS, Kermode JA, Downie SR, Brown NJ, Hardaker KM, Berend N, King GG, Salome CM: Obesity Is a Determinant of Asthma Control. 2011, Chest: Independent of Inflammation and Lung Mechanics
6.
go back to reference Prescott G, Woodruff BM: T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009, 180: 388-395. 10.1164/rccm.200903-0392OC.CrossRef Prescott G, Woodruff BM: T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009, 180: 388-395. 10.1164/rccm.200903-0392OC.CrossRef
7.
go back to reference Zeki AA, Kenyon NJ, Goldkorn T: Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research. Drug Metab Lett. 2011, 5 (1): 40-44. 10.2174/187231211794455217.PubMedCrossRef Zeki AA, Kenyon NJ, Goldkorn T: Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research. Drug Metab Lett. 2011, 5 (1): 40-44. 10.2174/187231211794455217.PubMedCrossRef
8.
go back to reference Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature. 1990, 343 (6257): 425-430. 10.1038/343425a0.PubMedCrossRef Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature. 1990, 343 (6257): 425-430. 10.1038/343425a0.PubMedCrossRef
9.
go back to reference Kume H: RhoA/Rho-kinase as a therapeutic target in asthma. Curr Med Chem. 2008, 15 (27): 2876-2885. 10.2174/092986708786242831.PubMedCrossRef Kume H: RhoA/Rho-kinase as a therapeutic target in asthma. Curr Med Chem. 2008, 15 (27): 2876-2885. 10.2174/092986708786242831.PubMedCrossRef
10.
go back to reference Chiba Y, Matsusue K, Misawa M: RhoA, a possible target for treatment of airway hyperresponsiveness in bronchial asthma. J Pharmacol Sci. 2010, 114 (3): 239-247. 10.1254/jphs.10R03CR.PubMedCrossRef Chiba Y, Matsusue K, Misawa M: RhoA, a possible target for treatment of airway hyperresponsiveness in bronchial asthma. J Pharmacol Sci. 2010, 114 (3): 239-247. 10.1254/jphs.10R03CR.PubMedCrossRef
11.
go back to reference McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY: A Novel Anti-Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma. J Immunol. 2004, 172 (5): 2903-2908.PubMedCrossRef McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY: A Novel Anti-Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma. J Immunol. 2004, 172 (5): 2903-2908.PubMedCrossRef
12.
go back to reference Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H: Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. AmJ Respir Cell Mol Biol. 2006, 35 (6): 722-729. 10.1165/rcmb.2006-0034OC.CrossRef Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H: Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. AmJ Respir Cell Mol Biol. 2006, 35 (6): 722-729. 10.1165/rcmb.2006-0034OC.CrossRef
13.
go back to reference Stanek EJ, Aubert RE, Xia F, Frueh FW, Sanders C, Weiss ST, Epstein RS: Impact of statin therapy on asthma-related event costs in adult asthma patients. Value Health. 2009, 12 (3): A121-A122.CrossRef Stanek EJ, Aubert RE, Xia F, Frueh FW, Sanders C, Weiss ST, Epstein RS: Impact of statin therapy on asthma-related event costs in adult asthma patients. Value Health. 2009, 12 (3): A121-A122.CrossRef
14.
go back to reference Feschenko Y, Lashyna L, Kramarskaya N, Polianska M, Matvienko J: Clinical and functional effectiveness of atorvastatin in complex therapy of severe bronchial asthma [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4–8. 2009, [E4554]. Feschenko Y, Lashyna L, Kramarskaya N, Polianska M, Matvienko J: Clinical and functional effectiveness of atorvastatin in complex therapy of severe bronchial asthma [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4–8. 2009, [E4554].
15.
go back to reference Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ: Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010, 126: 754-762. 10.1016/j.jaci.2010.08.005. e751.PubMedCrossRef Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ: Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010, 126: 754-762. 10.1016/j.jaci.2010.08.005. e751.PubMedCrossRef
16.
go back to reference Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, Lafferty J, Lloyd SM, Spears M, Mair F, et al: Effects of short-term treatment with atorvastatin in smokers with asthma–a randomized controlled trial. BMC Pulm Med. 2011, 11: 16-10.1186/1471-2466-11-16.PubMedPubMedCentralCrossRef Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, Lafferty J, Lloyd SM, Spears M, Mair F, et al: Effects of short-term treatment with atorvastatin in smokers with asthma–a randomized controlled trial. BMC Pulm Med. 2011, 11: 16-10.1186/1471-2466-11-16.PubMedPubMedCentralCrossRef
17.
go back to reference Christiansen SC, Schatz M, Eddleston J, Wagelie-Steffen A, Yang SJ, Chen W, Zuraw BL: HMG-CoA reductase inhibitors and asthma severity. J Allergy ClinImmunol. 2009, 123 (2): S84-CrossRef Christiansen SC, Schatz M, Eddleston J, Wagelie-Steffen A, Yang SJ, Chen W, Zuraw BL: HMG-CoA reductase inhibitors and asthma severity. J Allergy ClinImmunol. 2009, 123 (2): S84-CrossRef
18.
go back to reference Ostroukhova M, Kouides RW, Friedman E: The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol. 2009, 103 (6): 463-468. 10.1016/S1081-1206(10)60261-X.PubMedCrossRef Ostroukhova M, Kouides RW, Friedman E: The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol. 2009, 103 (6): 463-468. 10.1016/S1081-1206(10)60261-X.PubMedCrossRef
19.
go back to reference Foumani S, Nejatifar F, Forghan Parast K, Heidarinejad S, Mortazhejri G: Effects of atorvastatin in asthmatic patients under treatment with high dose inhaled or oral steroid [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18–22. 2010, [372]. Foumani S, Nejatifar F, Forghan Parast K, Heidarinejad S, Mortazhejri G: Effects of atorvastatin in asthmatic patients under treatment with high dose inhaled or oral steroid [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18–22. 2010, [372].
20.
go back to reference Jadad AR: Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?. Controlled Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.PubMedCrossRef Jadad AR: Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?. Controlled Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.PubMedCrossRef
21.
go back to reference Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ: Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol. 2007, 119: 328-335. 10.1016/j.jaci.2006.10.014.PubMedCrossRef Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ: Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol. 2007, 119: 328-335. 10.1016/j.jaci.2006.10.014.PubMedCrossRef
22.
go back to reference Hothersall EJ, Chaudhuri R, McSharry C, Donnelly I, Lafferty J, McMahon AD, Weir CJ, Meiklejohn J, Sattar N, McInnes I, et al: Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008, 63: 1070-1075. 10.1136/thx.2008.100198.PubMedCrossRef Hothersall EJ, Chaudhuri R, McSharry C, Donnelly I, Lafferty J, McMahon AD, Weir CJ, Meiklejohn J, Sattar N, McInnes I, et al: Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008, 63: 1070-1075. 10.1136/thx.2008.100198.PubMedCrossRef
23.
go back to reference Fahimi F, Jamaati H, Taheri ZM, Fakharian A, Salamzadeh J: Does atorvastatin have effect on lung function and morbidity as add on therapy in asthmatic patients? [Abstract]. Eur Respir J. 2007, 490s: 2960- Fahimi F, Jamaati H, Taheri ZM, Fakharian A, Salamzadeh J: Does atorvastatin have effect on lung function and morbidity as add on therapy in asthmatic patients? [Abstract]. Eur Respir J. 2007, 490s: 2960-
24.
go back to reference Moini A, Azimi G, Farivar A: Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res. 2012, 4 (5): 290-294. 10.4168/aair.2012.4.5.290.PubMedPubMedCentralCrossRef Moini A, Azimi G, Farivar A: Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res. 2012, 4 (5): 290-294. 10.4168/aair.2012.4.5.290.PubMedPubMedCentralCrossRef
25.
go back to reference Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR: Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax. 2010, 65: 891-896. 10.1136/thx.2010.138990.PubMedCrossRef Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR: Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax. 2010, 65: 891-896. 10.1136/thx.2010.138990.PubMedCrossRef
26.
go back to reference Pagovich O, Wang E, Lee-Wong M: Statins may improve asthma. J Allergy Clin Immunol. 2010, 125 (2): AB45-CrossRef Pagovich O, Wang E, Lee-Wong M: Statins may improve asthma. J Allergy Clin Immunol. 2010, 125 (2): AB45-CrossRef
27.
go back to reference Adams R, Appleton S, Wilson D, Ruffin R: Effects of lipid lowering therapy in a representative asthma population. Respirology. 2010, 15: A46- Adams R, Appleton S, Wilson D, Ruffin R: Effects of lipid lowering therapy in a representative asthma population. Respirology. 2010, 15: A46-
28.
go back to reference Moskovljevic J, Zivkovic M: Effect on lung function and morbidity in asthmatic patients who use atorvastatin. Allergy: Eur J Allergy Clin Immunol. 2010, 65: 526- Moskovljevic J, Zivkovic M: Effect on lung function and morbidity in asthmatic patients who use atorvastatin. Allergy: Eur J Allergy Clin Immunol. 2010, 65: 526-
29.
go back to reference Al Obaidi AHA, Al Samarai AGM: Evaluation anti-inflammatory and anti-oxidant activity of simvastatin in asthma. J Bahrain Med Soc. 2008, 20 (2): 55-59. Al Obaidi AHA, Al Samarai AGM: Evaluation anti-inflammatory and anti-oxidant activity of simvastatin in asthma. J Bahrain Med Soc. 2008, 20 (2): 55-59.
30.
go back to reference Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB: Statin use in patients with asthma - a nationwide population-based study. Eur J Clin Invest. 2011, 41 (5): 507-512. 10.1111/j.1365-2362.2010.02434.x.PubMedCrossRef Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB: Statin use in patients with asthma - a nationwide population-based study. Eur J Clin Invest. 2011, 41 (5): 507-512. 10.1111/j.1365-2362.2010.02434.x.PubMedCrossRef
31.
go back to reference Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y: Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open. 2012, 2 (3): 10.1136/bmjopen-2012-001279. Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y: Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open. 2012, 2 (3): 10.1136/bmjopen-2012-001279.
32.
go back to reference Enright PL, Newman AB: Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. 1999, 116: 603-613. Enright PL, Newman AB: Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. 1999, 116: 603-613.
33.
go back to reference Parameswaran K: Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med. 1998, 92: 573-577. 10.1016/S0954-6111(98)90311-0.PubMedCrossRef Parameswaran K: Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med. 1998, 92: 573-577. 10.1016/S0954-6111(98)90311-0.PubMedCrossRef
34.
go back to reference Hartert TV: Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc. 2000, 48: 651-657.PubMedCrossRef Hartert TV: Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc. 2000, 48: 651-657.PubMedCrossRef
35.
go back to reference Alexeeff SE: Statin Use Reduces Decline in Lung Function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007, 176: 742-747. 10.1164/rccm.200705-656OC.PubMedPubMedCentralCrossRef Alexeeff SE: Statin Use Reduces Decline in Lung Function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007, 176: 742-747. 10.1164/rccm.200705-656OC.PubMedPubMedCentralCrossRef
36.
go back to reference Keddissi JI: The Use of Statins and Lung Function in Current and Former Smokers. Chest. 2007, 132 (6): 1764-1771. 10.1378/chest.07-0298.PubMedCrossRef Keddissi JI: The Use of Statins and Lung Function in Current and Former Smokers. Chest. 2007, 132 (6): 1764-1771. 10.1378/chest.07-0298.PubMedCrossRef
37.
go back to reference Boulet LP, Franssen E: Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007, 101: 2240-2247. 10.1016/j.rmed.2007.06.031.PubMedCrossRef Boulet LP, Franssen E: Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007, 101: 2240-2247. 10.1016/j.rmed.2007.06.031.PubMedCrossRef
38.
go back to reference Lavoie KL, Bacon SL, Labrecque M, et al: Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med. 2006, 100: 648-657. 10.1016/j.rmed.2005.08.001.PubMedCrossRef Lavoie KL, Bacon SL, Labrecque M, et al: Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med. 2006, 100: 648-657. 10.1016/j.rmed.2005.08.001.PubMedCrossRef
39.
go back to reference Forno E, Lescher R: Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011, 127 (3): 741-749. 10.1016/j.jaci.2010.12.010.PubMedPubMedCentralCrossRef Forno E, Lescher R: Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011, 127 (3): 741-749. 10.1016/j.jaci.2010.12.010.PubMedPubMedCentralCrossRef
40.
go back to reference Rolfe BE, Worth NF: Rho and vascular disease. Atherosclerosis. 2005, 183 (1): 1-16. 10.1016/j.atherosclerosis.2005.04.023.PubMedCrossRef Rolfe BE, Worth NF: Rho and vascular disease. Atherosclerosis. 2005, 183 (1): 1-16. 10.1016/j.atherosclerosis.2005.04.023.PubMedCrossRef
41.
go back to reference Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al: Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Nat Acad Sci USA. 2002, 99 (24): 15345-15350. 10.1073/pnas.232551499.PubMedPubMedCentralCrossRef Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al: Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Nat Acad Sci USA. 2002, 99 (24): 15345-15350. 10.1073/pnas.232551499.PubMedPubMedCentralCrossRef
42.
go back to reference Chu A, Ordonez ET, Hellerstein MK: Measurement of mouse vascular smooth muscle and atheroma cell proliferation by 2H2O incorporation into DNA. Am J Physiol Cell Physiol. 2006, 291 (5): C1014-C1021. 10.1152/ajpcell.00191.2006.PubMedCrossRef Chu A, Ordonez ET, Hellerstein MK: Measurement of mouse vascular smooth muscle and atheroma cell proliferation by 2H2O incorporation into DNA. Am J Physiol Cell Physiol. 2006, 291 (5): C1014-C1021. 10.1152/ajpcell.00191.2006.PubMedCrossRef
43.
go back to reference Knapp AC, Huang J, Starling G: Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000, 152: 217-227. 10.1016/S0021-9150(99)00462-1.PubMedCrossRef Knapp AC, Huang J, Starling G: Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000, 152: 217-227. 10.1016/S0021-9150(99)00462-1.PubMedCrossRef
44.
go back to reference Hilgendorff A, Muth H, Parviz B: Statins differ in their ability to block NFkB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003, 41: 397-401.PubMedCrossRef Hilgendorff A, Muth H, Parviz B: Statins differ in their ability to block NFkB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003, 41: 397-401.PubMedCrossRef
45.
go back to reference Kiener PA, Davis PM, Murray JL: Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001, 1: 105-118. 10.1016/S0162-3109(00)00272-1.PubMedCrossRef Kiener PA, Davis PM, Murray JL: Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol. 2001, 1: 105-118. 10.1016/S0162-3109(00)00272-1.PubMedCrossRef
46.
go back to reference Amir A, Zeki JMB: Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?. Transl Res. 2010, 156: 335-349. 10.1016/j.trsl.2010.09.003.CrossRef Amir A, Zeki JMB: Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?. Transl Res. 2010, 156: 335-349. 10.1016/j.trsl.2010.09.003.CrossRef
Metadata
Title
Statins as potential therapeutic drug for asthma?
Authors
Cheng Yuan
Lin Zhou
Jiyun Cheng
Jingying Zhang
Yue Teng
Mao Huang
Ian M Adcock
Peter J Barnes
Xin Yao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2012
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-13-108

Other articles of this Issue 1/2012

Respiratory Research 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine